Trends in utilization and spending on remote monitoring of pacemakers and implantable cardioverter-defibrillators among Medicare beneficiaries

被引:12
|
作者
Holtzman, Jessica N. [1 ,2 ]
Wadhera, Rishi K. [1 ,2 ]
Choi, Eunhee [1 ,2 ]
Zhao, Tianyi [1 ,2 ]
Secemsky, Eric A. [1 ,2 ]
Fraiche, Ariane M. [1 ,2 ]
Shen, Changyu [1 ,2 ]
Kramer, Daniel B. [1 ,2 ]
机构
[1] Beth Israel Deaconess Med Ctr, Richard A & Susan F Smith Ctr Outcomes Res Cardio, Boston, MA 02215 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
关键词
Health care costs; Health services utilization; Implantable cardioverter-defibrillator; Pacemaker; Remote monitoring; FOLLOW-UP; ELECTRONIC DEVICES; ATRIAL-FIBRILLATION; INTERROGATION;
D O I
10.1016/j.hrthm.2020.05.044
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND National trends and costs associated with remote and in-office interrogations of pacemakers and implantable cardioverter-defibrillators (ICDs) have not been previously described. OBJECTIVE The purpose of this study was to evaluate utilization and Medicare spending for remote monitoring and in-office interrogations for pacemakers and ICDs. METHODS We performed a retrospective cohort study of claims and spending for remote and in-office interrogations of pacemakers and ICDs for Medicare fee-for-service beneficiaries from 2012 to 2015. Aggregate and per-beneficiary claims and spending were calculated for each device type. RESULTS Among all patients, 41.9% were female and the mean age was 78.3 years. From 2012 to 2015, remote monitoring utilization increased sharply. Aggregate professional remote monitoring claims for pacemakers increased by 61.3% and for ICDs by 5.6%, with an increase in technical claims (combined for pacemakers and ICDs) of 32. 8%. Spending on all remote and in-office interrogations for these devices totaled $160 million per year, with remote costs increasing nearly 25% from $45.4 million in 2012 to $56.7 million in 2015. At the beneficiary level, remote interrogations increased for pacemakers from 0.6 to 0.9 per year, and for ICDs from 1.3 to 1.4 per year, whereas in-office interrogations decreased from 2.8 to 2.7 per year and from 3.0 to 2.9 per year, respectively. Beneficiary-level analysis revealed increased expenditures on remote interrogation offset by decreases in in-office expenditures, with total annual spending decreasing by $2 and $5 per beneficiary, respectively. CONCLUSION Remote monitoring utilization increased substantially from 2012 to 2015, whereas annual costs per beneficiary decreased.
引用
收藏
页码:1917 / 1921
页数:5
相关论文
共 50 条
  • [1] Patient and Provider Perspectives on Remote Monitoring of Pacemakers and Implantable Cardioverter-Defibrillators
    Fraiche, Ariane M.
    Matlock, Daniel D.
    Gabriel, Wilanda
    Rapley, Faith-Anne
    Kramer, Daniel B.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2021, 149 : 42 - 46
  • [2] Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure
    Hernandez, Adrian F.
    Fonarow, Gregg C.
    Hammill, Bradley G.
    Al-Khatib, Sana M.
    Yancy, Clyde W.
    O'Connor, Christopher M.
    Schulman, Kevin A.
    Peterson, Eric D.
    Curtis, Lesley H.
    [J]. CIRCULATION-HEART FAILURE, 2010, 3 (01) : 7 - 13
  • [3] Racial and gender trends in the use of implantable cardioverter-defibrillators among medicare beneficiaries between 1997 and 2003
    Chan, Paul S.
    Birkmeyer, John D.
    Krumholz, Harlan M.
    Spertus, John A.
    Nallamothu, Brahmajee K.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A254 - A254
  • [4] Troubleshooting pacemakers and implantable cardioverter-defibrillators
    Scher, DL
    [J]. CURRENT OPINION IN CARDIOLOGY, 2004, 19 (01) : 36 - 46
  • [5] Deactivation of Pacemakers and Implantable Cardioverter-Defibrillators
    Kramer, Daniel B.
    Mitchell, Susan L.
    Brock, Dan W.
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 2012, 55 (03) : 290 - 299
  • [6] Use of Implantable Cardioverter-Defibrillators Among Medicare Patients
    Forman, Daniel E.
    Maurer, Mathew S.
    Rich, Michael W.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (17): : 1873 - 1874
  • [7] Remote monitoring and follow-ups of pacemakers and implantable cardioverter-defibrillators in the elderly patients
    Safarikova, I.
    Hajek, P.
    Bulava, A.
    [J]. ACTA CARDIOLOGICA, 2019, 74 (05) : 444 - 444
  • [8] The frequency and incremental cost of major complications among Medicare beneficiaries receiving implantable cardioverter-defibrillators
    Reynolds, MR
    Cohen, DJ
    Kugelmass, AD
    Brown, PP
    Becker, ER
    Culler, SD
    Simon, AW
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (12) : 2493 - 2497
  • [9] Psychosocial impact of pacemakers and implantable cardioverter-defibrillators
    Candinas, R
    Buchi, S
    Klaghofer, R
    Sensky, T
    Buddeberg, C
    Duru, F
    [J]. XXI CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY, 1999, : 857 - 862
  • [10] Pacemakers and implantable cardioverter-defibrillators in pediatric patients
    Silka, Michael J.
    Bar-Cohen, Yaniv
    [J]. HEART RHYTHM, 2006, 3 (11) : 1360 - 1366